
Medical Properties Trust has had a tough five year stretch, even as the current valuation signals are more balanced, with an intrinsic value estimate pointing to roughly fair pricing while market multiples suggest the stock may be cheap on some measures.
The issue now is whether Medical Properties Trust's current share price already reflects these risks and cash flow prospects, or if there is still a meaningful discount or premium to its intrinsic value estimate.
Compare Medical Properties Trust's mixed valuation signal with other potential opportunities by scanning 50 high quality undervalued stocks, which also pair cash flow support with compressed market expectations.
The Discounted Cash Flow (DCF) model here uses adjusted funds from operations to value Medical Properties Trust. The latest twelve month free cash flow is about $183.9 million, and the model assumes cash flows grow from this base rather than shrink. On that basis, the intrinsic value per share is estimated at about $4.33.
Against the current share price, this points to roughly a 6.8% gap, which suggests Medical Properties Trust is about fairly valued rather than offering a large margin of safety. Given the reliance on a gradual recovery profile for future cash flows, the outcome appears balanced rather than extreme in either direction.
Overall, the DCF work up indicates Medical Properties Trust shares are about fairly valued at current levels.
Medical Properties Trust is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.
P/S is often a useful yardstick for a REIT like Medical Properties Trust because revenue is more stable than accounting earnings, which can swing around depreciation and one off items. Medical Properties Trust currently trades on a P/S of about 2.2x, compared with a Health Care REITs industry average of roughly 6.5x and a peer group average near 4.8x.
The model based fair P/S ratio for Medical Properties Trust is higher again, at about 6.2x. That is well above the current 2.2x level. This implies the stock changes hands at a sizeable discount to what this framework suggests could be reasonable given its profile and risk mix. This gap aligns with the earlier DCF work, which also pointed to a valuation that is not stretched on cash flow assumptions.
On the P/S multiple, Medical Properties Trust stock screens as undervalued compared with both its sector and the model based fair ratio.
See what the numbers say about this price — find out in our valuation breakdown.
Simply Wall St Narratives pick up where the Medical Properties Trust valuation puzzle leaves off. They spell out which assumptions about Medical Properties Trust's future growth, margins and earnings would need to hold for the stock to be worth significantly more or less than it is today. Each one links a fair value estimate to a specific mix of potential catalysts and risks so you can track over time which version of events seems to be gaining traction. They sit on Simply Wall St's Community page.
One of the top community narratives on Medical Properties Trust: 21% undervalued
"Successful refinancing of large European JVs at attractive fixed rates and the ability to attract strong institutional investor interest underscores ongoing access to affordable capital…"
Read one of the top narratives on Medical Properties Trust
Do you think there's more to the story for Medical Properties Trust? Head over to our Community to see what others are saying!
Medical Properties Trust screens as roughly fairly valued on a Discounted Cash Flow (DCF) view, with only a modest gap between the intrinsic value estimate and the market price. The P/S multiple points to an undervalued stock compared with sector peers and a model based fair ratio, which suggests sentiment remains cautious. That mix keeps the overall read as balanced rather than aggressively cheap. The key swing factor from here is whether Medical Properties Trust can sustain and collect its cash flows while managing tenant concentration and balance sheet pressure well enough for the market to narrow that discount without adding extra risk.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com